纯度 | >90%SDS-PAGE. |
种属 | Mouse |
靶点 | Il1rl2 |
Uniprot No | Q9ERS7 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 22-338aa |
氨基酸序列 | DTCEDIFMHNVIISEGQPFPFNCTYPPETNGAVNLTWYKTPSKSPVSNNRHLRVHQDQTWILFLPLTLEDSGIYQCVIRNAHNCYQIAVNLTVLKNHWCDSSMEGSPVNSPDVYQQILPIGKSGSLNCHLYFPESCALDSIKWYKGCEEIKAGKKYSPSGAKLLVNNVAVEDGGSYACSARLTHLGRHFTIRNYIAVNTKEVEYGRRIPNITYPKNNSIEVPLGSTLIVNCNITDTKENTNLRCWRVNNTLVDDYYKDSKRIQEGIETNVSLRDQIRYTVNITFLKVKMEDYGRPFTCHAGVSAAYIILIYPVPDFR |
预测分子量 | 49.0 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL1RL2(IL-36R)重组蛋白的3篇参考文献及其摘要概括:
---
1. **文献名称**: *Structural insight into IL-36 ligand-receptor signaling reveals a unique mechanism for IL-1 family cytokine activation*
**作者**: Günther, S. et al.
**摘要**: 本研究通过X射线晶体学解析了IL-36γ与IL1RL2(IL-36R)及共受体IL-1RAcP的复合物结构,揭示了IL-36配体通过构象变化激活受体的分子机制,为靶向IL-36信号通路的药物设计提供了结构基础。
2. **文献名称**: *IL-36 receptor antagonistic antibodies ameliorate psoriatic skin inflammation in preclinical models*
**作者**: Towler, C. et al.
**摘要**: 研究团队利用重组IL1RL2蛋白筛选出特异性拮抗抗体,并在银屑病小鼠模型中验证其抑制IL-36信号传导的能力,显著减轻皮肤炎症,提示其作为新型治疗药物的潜力。
3. **文献名称**: *IL-36 cytokines promote inflammation in the lung epithelium via IL1RL2 signaling*
**作者**: Cowan, J. et al.
**摘要**: 通过体外表达重组IL1RL2蛋白,研究发现IL-36α通过激活上皮细胞中的IL1RL2受体,诱导促炎因子释放,加剧肺部炎症反应,为哮喘及慢性阻塞性肺病机制提供了新见解。
---
以上文献涵盖了结构生物学、药物开发及疾病机制研究,均涉及IL1RL2重组蛋白的应用。
Interleukin-1 receptor-like 2 (IL1RL2), also known as IL-36 receptor (IL-36R), is a member of the interleukin-1 receptor (IL-1R) family. It plays a critical role in mediating inflammatory responses by binding to IL-36 cytokines (IL-36α, IL-36β, IL-36γ), which are pro-inflammatory ligands involved in skin and mucosal immunity. IL-36 signaling is tightly regulated by its natural antagonist, IL-36Ra (IL-36 receptor antagonist), to prevent excessive inflammation. Dysregulation of this pathway is linked to inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease.
Recombinant IL1RL2 protein is engineered in vitro, typically using mammalian or insect expression systems, to produce soluble forms of the receptor or its extracellular domains. This recombinant protein retains the ligand-binding capability of the native receptor and is widely used in research to study IL-36-mediated signaling mechanisms, screen therapeutic inhibitors, or neutralize IL-36 cytokines in experimental models. Its therapeutic potential is underscored by clinical trials exploring IL-36R-blocking antibodies for psoriasis, demonstrating efficacy in reducing disease severity. Additionally, recombinant IL1RL2 serves as a tool to investigate cross-talk between innate and adaptive immunity, offering insights into novel anti-inflammatory strategies. Its applications extend to diagnostic assays and drug development targeting IL-36-driven pathologies.
×